Introduction {#s1}
============

Scleroderma (systemic sclerosis, SSc) is a chronic complex autoimmune disease characterised by (*a*) organ fibrosis involving the skin, lungs, gastrointestinal tract and/or heart; (*b*) a proliferative vasculopathy primarily affecting small blood vessels and capillaries; (*c*) immune activation with production of disease-specific autoantibodies.[@R1]--[@R4] The disease is further classified into limited and diffuse forms based on extent and distribution of cutaneous thickening.

The most common SSc-specific autoantibodies are directed against centromeric proteins anticentromere (ACA) (CENP B and A), anti-topoisomerase I (ATA) (also termed Scl-70) and anti-RNA polymerase III (ARA); however, a variety of less common specificities, typically antinucleolar, can be found, which include anti-U3 ribonucleoprotein (fibrillarin) AFA), anti-Th/To, anti-Pm-Scl, anti-RNA polymerase I and anti-U1-ribonucleoprotein (RNP).[@R5] Importantly, each patient with SSc typically produces only one of these autoantibodies and each one currently serves as a biomarker for different patterns of skin and visceral involvement, as well as prognosis. In addition, certain SSc-specific antibodies occur in different frequencies among different ethnic groups.

Scleroderma is thought to be a complex genetic disease, influenced by multiple genes, with a substantial environmental or non-germline component based on twin studies.[@R6] African-American and Hispanic patients with scleroderma tend to have more severe disease than their Caucasian counterparts and disease in African-American subjects begins at an earlier age.[@R7] The Choctaw Indians of southeastern Oklahoma have a nearly 10-fold prevalence of the disease compared with other ethnicities.[@R8] It appears likely that there are different combinations of genes, the interacting effects of which influence disease susceptibility and severity. Recently, we have found that the same polymorphism in the *PTPN22* gene associated with rheumatoid arthritis, systemic lupus erythematosus and other autoimmune diseases is also associated with SSc, especially in those patients having ATA or ACA antibodies.[@R9]--[@R11] Additional 'autoimmunity' genes now reported to be associated with SSc include allograft inflammatory factor, *IL1A*, *IRF5*, *STAT4* and *FAS*.[@R12]--[@R16]

Major histocompatibility complex (MHC) or human leucocyte antigen-class II (HLA-class II) allelic associations with SSc have been reported in European and North American Caucasian subjects (*DRB1\*0301*, *DRB1\*11*, *DRB1\*07*) and Japanese and Koreans (*DRB1\*1502*) over the past two decades but have been relatively weak.[@R5] [@R17]--[@R22] Much stronger correlations, however, have been demonstrated between certain HLA-class II alleles and each of the SSc-specific autoantibodies.[@R21] [@R23]--[@R27] Different HLA-*DRB1*, *DQB1*, *DQA1* and/or *DPB1* alleles, or combinations thereof, are associated with expression of ACA (*DQB1\*0501* and other *DQB1* alleles encoding non-leucine residues at position 26 in the peptide binding groove),[@R21] [@R25] [@R27] ATA (*DRB1\*11*, especially the *DRB1\*1104*, *DQB1\*0301* haplotype) in Caucasian subjects and *DRB1\*1502*, *DQB1\*0601* in Japanese and Korean subjects,[@R21]--[@R23] AFA antibody (the *DRB1\*1302*, *DQB1\*0604* haplotype),[@R24] and anti-PM-Scl (*DRB1\*0301*).[@R26] No consistent HLA correlations heretofore have been made with ARA.[@R28] [@R29] [@R38]--[@R40] Only a few studies have examined HLA-*DPB1* alleles in SSc; however, one such allele (*DPB1\*1301*) has been associated with ATA.[@R30]--[@R32] It has been unclear whether this allele is an independent disease correlate or the result of linkage disequilibrium (LD) with HLA-*DRB1* and *DQB1* haplotypes. Although genetic influences are thought to have an important role in susceptibility to SSc, genetic studies of scleroderma have included relatively small numbers of patients, especially black and Hispanic subjects. HLA associations with specific autoantibodies may be clinically relevant because each of the autoantibody subsets of scleroderma is associated with certain disease features and different prognostic implications.

Thus, the overall aims of this study were to determine specific HLA-class II alleles, haplotypes and epitopes influencing susceptibility to, and/or expression of, SSc itself, its limited or diffuse forms, or its various autoantibody subsets across ethnic lines in the largest cohort yet of American patients.

Methods {#s2}
=======

Selection of SSc cases and normal controls {#s3}
------------------------------------------

A case--control association study was performed (total SSc cases 1300; total controls 1000) along with subanalyses by ethnicity, gender, clinical subsets and specific autoantibody profiles. Patients were included from the NIH/NIAMS Scleroderma Family Registry and DNA Repository,[@R33] the Genetics versus Environment in Scleroderma Outcomes Study (GENISOS) cohort followed up in the NIH/NIAMS Center of Research Translation in Scleroderma,[@R6] and the UT-Houston Rheumatology Division. Patients with SSc included 961 Caucasian, 178 African-American and 161 Hispanic subjects; normal local control totals were 539 Caucasian, 263 African-American and 198 Hispanic subjects.Only Hispanic patients with SSc and controls of Mexican or Central American ancestry were included.

HLA-*DPB1* alleles were determined in 705 Caucasian patients with SSc and 287 Caucasian controls in the Scleroderma Registry. Only 82 African-American and Hispanic cases were studied for HLA-*DPB1* alleles but were added to the Caucasian subjects for an overall comparison. All patients fulfilled the preliminary American College of Rheumatology criteria for the diagnosis of SSc[@R34] or had three of the five clinical features of the CREST syndrome (calcinosis, Raynaud\'s phenomenon, esophageal dysfunction, sclerodactyly or telangiectasia). Patients having overlapping Sjögren\'s syndrome, myositis or features of rheumatoid arthritis or systemic lupus were not excluded. Results of HLA allele frequencies in some of these patients have been reported previously[@R23]--[@R25] [@R30] and are included here. Because of the cross-sectional nature of two of these three cohorts, reliable clinical information on specific organ involvement, such as pulmonary fibrosis, pulmonary hypertension or renal crisis, was not available to assess HLA associations. HLA registry controls were primarily spouse or friend controls, and GENISOS/Division controls were healthy medical centre personnel or blood bank donors from the local Houston area. All controls were screened for a history of any autoimmune diseases and excluded if positive. All study subjects provided written informed consent and the study was approved by the UTH Committee for the Protection of Human Subjects.

Autoantibody identification {#s4}
---------------------------

Antinuclear antibodies and ACA were determined in all patients with SSc by indirect immunofluorescence on HEp-2 cells (Antibodies, Davis, California, USA). Immunodiffusion against calf thymus extract was used to determine the presence of ATA (Scl-70), anti-Ro/SS-A, anti-La/SS-B, anti-Smith (Sm) and anti-RNP autoantibodies (Inova Diagnostics, San Diego, California, USA). ARA were determined using a commercially available enzyme-linked immunoassay (EIA) kit (MBL, Nagoya, Japan). AFA were determined only in those Division and GENISOS patients with SSc with a nucleolar antinuclear antibody pattern using immunoprecipitation.

HLA-class II genotyping {#s5}
-----------------------

HLA-*DQA1*, *-DQB1* and -*DPB1* alleles were oligotyped and *DRB1* alleles directly sequenced from extracted genomic DNA as previously described.

Statistical analyses {#s6}
--------------------

We used statistical analysis software SAS 9.1.3 and the SAS Genetic Package (SAS Institute, Cary, North Carolina, USA). χ^2^ Tests or Fisher\'s exact tests were used to compare HLA-class II allele frequencies between the normal control and SSc groups. Mantel--Haenszel tests were performed for the analysis of HLA-class II allelic frequencies to control for the confounding effects of ethnicity. In the online supplementary tables, we only reported the odds ratio (OR) and the corresponding 95% CI for p values \<0.017, which accounts for the Bonferroni corrections by the number of comparisons for each HLA genotype (0.017 = 0.05/3). LD coefficients and the corresponding p values were computed to examine the allelic associations that occur between alleles at different loci using SAS Genetics software.

These χ^2^ data are presented in the supplementary tables. We then performed exact logistic regression for each of the HLA variants using dominant (D), additive (A) and recessive (R) modelling. To account for the multiple comparisons, we used a false discovery rate approach.[@R35] We used an experimental threshold of α = 0.05 and accounted for 1000 potential multiple comparisons that we performed. Using these values for α and number of tests performed, a point significance of 0.004 is considered statistically significant. Nonetheless, p values of \<0.05 also are selectively shown for alleles of interest and those which have been associated with SSc or its subgroups in other reports. Use of the 0.004 as the threshold to declare significance leads to a rough false discovery rate of 0.025. For LD analyses we used the procedure *haplotype* in the SAS Genetic Package. In addition, we examined frequencies of the presence of non-leucine residues at position 26 in the DQ β chain based on our previous studies implicating this 'epitope' (*DQB1\*26 epi*) in susceptibility to the ACA in SSc.[@R23] [@R25]

Results {#s7}
=======

HLA-class II alleles in SSc {#s8}
---------------------------

HLA-class II (*DRB1*, *DQA1* and *DQB1*[)]{.ul} genotyping was completed in 1300 SSc cases and 1000 normal controls and *HLA-DPB1* in 705 white SSc cases and 287 white controls ([tables 1](#T1){ref-type="table"}[--](#T2){ref-type="table"}[3](#T3){ref-type="table"} and supplementary [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### 

HLA-class II allelic frequencies significantly associated with Caucasian patients with systemic sclerosis (SSc) compared with Caucasian normal controls using logistic regression

                                         SSc (%)      Controls (%)   Model (D/R/A)   p Value    OR     95% CI
  -------------------------------------- ------------ -------------- --------------- ---------- ------ ------------
   \*0404                                4.3          1.9            D               0.003      2.33   1.3 to 4.1
   \*0701                                8.0          14.2           A               \<0.0001   0.39   0.1 to 1.1
  0.43                                   0.3 to 0.6                                                    
   \*11                                  13.5         8.2            D               0.0002     1.81   1.3 to 2.4
   \*1104                                7.1          3.0            D               \<0.0001   2.48   1.6 to 3.9
   \*1501                                11.0         14.3           R               0.0003     0.22   0.1 to 0.5
  DQA1[†](#T1FN1){ref-type="table-fn"}                                                                 
   \*0102                                18.1         21.3           R               0.0002     0.36   0.2 to 0.6
   \*0201                                7.6          14.4           A               \<0.0001   0.20   0.1 to 0.6
  0.43                                   0.3 to 0.6                                                    
   \*0501                                31.6         24.0           A               \<0.0001   2.29   1.4 to 3.7
  1.66                                   1.3 to 2.2                                                    
  DQB1[†](#T1FN1){ref-type="table-fn"}                                                                 
   \*0202                                5.4          10.3           D               \<0.0001   0.46   0.3 to 0.7
   \*0301                                23.0         16.8           D               0.002      1.50   1.2 to 1.9
   \*0602                                11.5         14.6           R               0.003      0.29   0.1 to 0.7
   \*DQB1 26 epi                         64.4         53.8           --              0.0003     1.59   1.2 to 2.0
  DPB1[‡](#T1FN2){ref-type="table-fn"}                                                                 
   \*1301                                3.7          1.4            D               0.004      3.18   1.4 to 7.3

SSc cases (n = 961) versus normal controls (n = 539);

SSc cases (n = 705) versus normal controls (n = 287) typed for HLA-DPB1.

###### 

HLA-class II allelic frequencies significantly associated with African-American patients with systemic sclerosis (SSc) compared with normal African-American controls using logistic regression

                                         SSc (%)      Controls (%)   Model (D/R/A)   p Value    OR     95% CI
  -------------------------------------- ------------ -------------- --------------- ---------- ------ ------------
  DRB1[†](#T2FN1){ref-type="table-fn"}                                                                 
   \*0804                                10.2         3.6            D               0.0003     3.31   1.7 to 6.5
  DQA1[†](#T2FN1){ref-type="table-fn"}                                                                 
   \*0501                                34.2         24.1           A               0.003      3.55   1.6 to 8.1
  1.63                                   1.1 to 2.5                                                    
  DQB1[†](#T2FN1){ref-type="table-fn"}                                                                 
   \*0301                                33.0         21.9           D               \<0.0001   2.44   1.6 to 3.7

SSc cases (n = 178) versus normal controls (n = 263).

For all white patients with SSc versus ethnically matched controls, a strong association was found with HLA-*DRB1\*11*, but specifically with *DRB1*\**1104* and not with *DRB1*\**1101*, *DQA1\*0501* and *DQB1\*0301* also were significantly increased. These three alleles constitute a haplotype with most *DRB\*11* alleles including both *DRB1\*1101* and *DRB1\*1104*.[@R36] Given the highest odds ratio (OR = 2.48) being conferred by *DRB1\*1104* rather than *DQA1\*0501* (OR = 2.29) or *DQB1\*0301* (OR = 1.50), the primary associated allele appeared likely to be *DRB1\*1104* in a dominant model. Also, the shared *DQB1\*26* epitope (absence of leucine in position 26) was increased (OR = 1.59). HLA-*DRB1\*0404* also was significantly increased (OR = 2.33); however, the strongest HLA-class II association with SSc was with HLA-*DPB1\*1301* (OR = 3.18). Testing for LD between HLA-*DPB1\*1301* and *DRB1\*1104* showed an r^2^ value of 0.0001 and for *DQB1\*0301* 0.009, thus demonstrating no significant LD of this DR/DQ haplotype with *DPB1\*1301*.

The HLA-*DRB1\*0701*, *DQA1\*0201*, *DQB1\*0202* haplotype was negatively associated with SSc in an additive model (HLA-*DRB1\*0701*, *DQA1\*0201*) and in dominant model (HLA- *DQB1\*0202*) suggesting that it conferred a 'protective' effect ([table 1](#T1){ref-type="table"}). Similarly, the HLA-*DRB1\*1501*, *DQA1\*0102*, *DQB1\*0602* haplotypes were significantly decreased but in a recessive model.

In African-Americans, the *HLA-DRB1\*0804/DQA1\*0501/DQB1\*0301* haplotype was significantly increased, while *DRB1\*1104* was not associated with SSc ([table 2](#T2){ref-type="table"}).

Significant associations with SSc in Hispanic subjects were found for *DRB1\*1104* (OR = 4.99), *DQA1\*0501* (OR = 4.09) and *DQB1\*0301* (OR = 2.13), along with the *DQB1\*26 epi* (OR = 1.81) ([table 3](#T3){ref-type="table"}). Again, *DRB1\*0701* and *DQA1\*0201* were decreased in frequency.

###### 

HLA-class II allelic frequencies significantly associated with Hispanic patients with systemic sclerosis (SSc) compared with normal Hispanic controls using logistic regression

                                         SSc (%)   Controls (%)   Model (D/R/A)   p Value   OR     95% CI
  -------------------------------------- --------- -------------- --------------- --------- ------ -------------
  DRB1[†](#T3FN1){ref-type="table-fn"}                                                             
   \*1104                                8.8       2.0            D               0.0003    4.99   2.0 to 12.4
   \*0701                                3.8       7.6            D               0.01      0.39   0.2 to 0.8
  DQA1[†](#T3FN1){ref-type="table-fn"}                                                             
   \*0501                                29.9      21.7           R               0.002     4.09   1.6 to 10.4
   \*0201                                3.8       7.8            D               0.01      0.39   0.2 to 0.8
  DQB1[†](#T3FN1){ref-type="table-fn"}                                                             
   \*0301                                24.2      14.9           D               0.003     2.13   1.3 to 3.5
   \*DQB1 26 epi                         72.7      61.7           --              0.019     1.81   1.1 to 3.0

SSc cases (n = 161) versus normal controls (n = 198).

HLA-*DQA1\*0501* was significantly more frequent in male (101/165 or 61%) than in female (583/1135 or 51%) patients with SSc (p = 0.02, OR = 1.49, 95% CI 1.06 to 2.12), thus confirming one earlier report.

HLA alleles in limited versus diffuse SSc {#s9}
-----------------------------------------

HLA associations with both limited and diffuse forms of SSc largely mirrored the findings in the disease group as a whole, except in black patients with limited disease whose numbers were small (n = 54) (supplementary tables 3a and 4a by logistic regression and supplementary [tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} by χ^2^).

HLA allele frequencies in autoantibody subsets of SSc {#s10}
-----------------------------------------------------

Frequencies and ethnic differences in SSc autoantibodies are shown in online supplementary [table 5](#T5){ref-type="table"}. ACA were found to be associated with several class II haplotypes in white subjects, including HLA-*DRB1\*0101*, *DQA1\*0101* and *DQB1\*0501*, *DRB1\*04*, especially *DRB1\*0404*, but weakly *DRB1\*0401* which carried *DQB1\*0301* alleles and weakly with *DRB1\*08* (*\*0801*) and *DQA1\*0401* ([table 4](#T4){ref-type="table"}, supplementary [table 6](#T6){ref-type="table"}). The strongest associated alleles were *DRB1\*0401* (OR = 8.98) in a recessive model, *DRB1\*0404* (OR = 4.18) in a dominant model, *DQB1\*0301* in a recessive model (OR = 3.41), *DQB1\*0501*(dominant OR = 2.56) and the *DQB1 26* epitope (OR = 2.93). No HLA-*DPB1* alleles were associated with ACA.

###### 

HLA-class II allelic frequencies significantly associated with antitopoisomerase I antibody positive Caucasian, African-American and Hispanic patients with systemic sclerosis (SSc) compared with ethnically matched normal controls using logistic regression

                                                     SSc (%)      Controls (%)   Model (D/R/A)   p Value    OR      95% CI
  -------------------------------------------------- ------------ -------------- --------------- ---------- ------- -------------
  Caucasian[†](#T5FN1){ref-type="table-fn"}                                                                         
   *DRB1*                                                                                                           
    \*0401                                           3.6          8.3            D               0.003      0.35    0.2 to 0.7
    1101                                             6.2          3.8            D               0.03       2.13    1.1 to 4.1
    \*1104                                           16.6         3.0            D               \<0.0001   6.93    3.9 to 12.2
   *DQA1*                                                                                                           
    \*0501                                           34.7         24.0           A               \<0.0001   2.01    0.9 to 4.7
  2.80                                               1.8 to 4.2                                                     
   *DQB1*                                                                                                           
    \*0202                                           5.2          10.3           D               0.006      0.44    0.2 to 0.8
    \*03                                             45.1         30.1           A               0.0004     3.30    1.8 to 6.2
  1.76                                               1.1 to 2.7                                                     
    \*0301                                           31.2         16.8           D               \<0.0001   3.20    2.1 to 4.8
    \*DQB1 26 epi                                    72.2         53.8           --              \<0.0001   2.47    1.6 to 3.8
   *DPB1*                                                                                                           
    \*1301                                           12.2         1.4            D               \<0.0001   14.02   6.5 to 30.3
  African-American[‡](#T5FN2){ref-type="table-fn"}                                                                  
   *DRB1*                                                                                                           
    \*08                                             12.5         5.5            D               0.04       2.64    1.1 to 6.1
    \*0804                                           11.3         3.6            D               0.01       3.42    1.3 to 9.0
    \*11                                             28.8         13.4           D               0.0005     3.55    1.8 to 7.2
    \*1101                                           12.5         5.7            D               0.13       1.98    0.8 to 4.9
    \*1104                                           8.8          1.9            D               0.007      4.66    1.6 to 13.4
   *DQB1*                                                                                                           
    \*0301                                           40.0         14.9           D               0.0002     3.90    1.9 to 8.1
    \*DQB1 26 epi                                    87.5         63.0           --              0.003      3.91    1.5 to 10.4
  Hispanic[§](#T5FN3){ref-type="table-fn"}                                                                          
   *DRB1*                                                                                                           
    \*08                                             23.6         9.9            D               0.08       2.00    0.9 to 4.4
    \*0802                                           20.8         8.3            D               0.13       1.91    0.8 to 4.3
    \*1104                                           22.2         2.0            D               \<0.0001   15.96   5.3 to 48.0
   *DQA1*                                                                                                           
    \*0401                                           26.4         9.1            D               0.008      3.05    1.4 to 6.7
    \*0301                                           24.3         14.9           D               0.01       2.88    1.3 to 6.3
   *DQB1*                                                                                                           
    \*0402                                           25.7         8.1            D               0.003      3.46    1.6 to 7.7
    \*DQB1 26 epi                                    78.4         61.7           --              0.03       2.59    1.1 to 6.1

SSc cases (n =154) versus normal controls (n = 539) in Caucasian subjects;

SSc cases (n = 40) versus normal controls (n = 263) in African-American subjects;

SSc cases (n = 37) versus normal controls (n = 198) in Hispanic subjects.

###### 

HLA-class II allelic frequencies significantly associated with anticentromere antibody positive Caucasian and Hispanic patients with systemic sclerosis (SSc) compared with ethnically matched normal controls using logistic regression

                                              SSc (%)       Controls (%)   Model (D/R/A)   p Value    OR     95% CI
  ------------------------------------------- ------------- -------------- --------------- ---------- ------ -------------
  Caucasian[†](#T4FN1){ref-type="table-fn"}                                                                  
  DRB1                                                                                                       
   \*01                                       21.0          12.5           D               \<0.0001   2.19   1.5 to 3.2
   \*0101                                     16.6          8.2            D               \<0.0001   2.72   1.8 to 4.1
   \*04                                       24.9          11.7           D               0.0004     1.90   1.3 to 2.7
   \*0401                                     11.0          8.3            R               0.03       8.98   1.4 to 57.2
   \*0404                                     5.5           1.9            D               \<0.0001   4.18   2.0 to 8.6
   \*0701                                     2.9           14.2           A               \<0.0001   0.10   0.01 to 0.8
                                                                                                      0.14   0.1 to 0.2
   \*08                                       6.1           3.4            D               0.04       1.90   1.1 to 3.4
   0801                                       4.8           2.0            D               0.03       3.17   1.5 to 6.6
   \*11                                       11.9          8.2            D               0.02       1.67   1.1 to 2.6
   \*1104                                     5.0           3.0                            NS                
   \*1501                                     8.9           14.3           R               0.006      0.67   0.4 to 1.02
  0.16                                        0.03 to 0.7                                                    
  *DQA1*                                                                                                     
   \*0101                                     23.1          13.4           D               \<0.0001   2.57   1.8 to 3.7
   \*0102                                     14.4          21.3           R               0.001      0.25   0.1 to 0.6
   \*0201                                     3.0           14.4           A               \<0.0001   0.07   0.01 to 0.6
  0.15                                        0.1 to 0.2                                                     
  *DQB1*                                                                                                     
   \*0202                                     5.3           2.8            D               \<0.0001   0.14   0.07 to 0.3
   \*0301                                     23.5          16.8           R               0.004      3.41   1.4 to 8.0
   \*0302                                     14.6          9.4            D               0.007      2.04   1.2 to 3.4
   \*0501                                     22.8          12.6           D               \<0.0001   2.56   2.0 to 3.7
   \*DQB1 26 epi                              75.1          53.8           --              \<0.0001   2.93   2.0 to 4.2
  *DPB1*                                                                                                     
   \*1301                                     1.5           1.4                            NS                
  Hispanic[‡](#T4FN2){ref-type="table-fn"}                                                                   
  *DRB1*                                                                                                     
   \*0407                                     26.0          6.8            D               0.0009     5.07   2.0 to 12.9

SSc cases (n = 281) versus normal controls (n = 539) in Caucasian subjects;

SSc cases (n = 25) versus normal controls (n = 198) in Hispanic subjects; NS=not significant for any of the three models

###### 

HLA-class II allelic frequencies significantly associated with anti-RNA polymerase III positive antibody positive Caucasian, African-American and Hispanic patients with systemic sclerosis (SSc) compared with ethnically matched normal controls using logistic regression.

                                                     SSc (%)         Controls (%)   Model (D/R/A)   p Value    OR      95% CI
  -------------------------------------------------- --------------- -------------- --------------- ---------- ------- -------------
  Caucasian[†](#T6FN1){ref-type="table-fn"}                                                                            
   *DRB1*                                                                                                              
    \*0404                                           7.5             1.9            D               \<0.0001   5.13    2.4 to 11.0
    \*11                                             12.4            8.2            A               0.02       6.78    1.2 to 37.7
  1.55                                               0.9 to 2.6                                                        
    \*1104                                           6.1             3.0            D               0.02       2.34    1.2 to 4.6
   *DQB1*                                                                                                              
    \*03                                             40.6            30.1           R               0.004      2.38    1.3 to 4.2
    \*0301                                           22.9            16.8           A               0.01       3.77    1.3 to 11.0
  1.50                                               1.002 to 2.26                                                     
  African-American[‡](#T6FN2){ref-type="table-fn"}                                                                     
   *DRB1*                                                                                                              
    \*08                                             13.6            5.5            D               0.003      3.92    1.7 to 9.2
    \*0804                                           9.1             3.6            D               0.05       2.98    1.04 to 8.5
    1104                                             3.0             1.9                            NS                 
   *DQA1*                                                                                                              
    \*0501                                           42.2            24.1           A               0.003      6.03    1.5 to 23.8
  3.10                                               1.3 to 7.2                                                        
   *DQB1*                                                                                                              
    \*0301                                           37.5            21.9           D               0.002      3.60    1.6 to 8.0
  Hispanic[§](#T6FN3){ref-type="table-fn"}                                                                             
   *DRB1*                                                                                                              
    \*11                                             12.5            5.6            D               0.10       2.17    2.0 to 11.6
    \*1104                                           3.8             2.0            D               0.005      10.50   2.3 to 46.8
   *DQA1*                                                                                                              
    \*0501                                           28.8            21.7           R               0.047      3.65    1.1 to 12.6
   *DQB1*                                                                                                              
    \*03                                             50.0            34.1           D               0.04       2.33    1.1 to 5.1
    \*0301                                           32.5            14.9           D               0.0002     4.07    2.0 to 8.5
    \*DQB1 26 epi                                    78.0            61.7           --              0.04       2.39    1.1 to 5.4

SSc cases (n = 182) versus normal controls (n = 539) in Caucasian subjects;

SSc cases (n = 33) versus normal controls (n = 263) in African-American subjects;

SSc cases (n = 40) versus normal controls (n = 198) in Hispanic subjects; NS=not significant for any of the three models

No HLA alleles were associated with ACA in black subjects and only *HLA-DRB1\*0407* in Hispanic subjects.

ATA in white subjects were strongly associated with the HLA-*DRB1\*1104*, *DQA1\*0501*, *DQB1\*0301* haplotype (OR = 6.93) and even more so with HLA-*DPB1\*1301* (OR = 14.02), both showing dominant models ([table 5](#T5){ref-type="table"}) (supplementary table 7).

The *DRB1\*1104* association also was present in the black subjects and Hispanic subjects, as was the *DQB1 26* epitope ([table 5](#T5){ref-type="table"}, supplementary table 7). In addition, *HLA*-*DRB1\*08* alleles, *DRB1\*0804* in black subjects (OR = 3.42) and *DRB1\*0802* in Hispanic subjects (OR = 1.91) also were increased in these groups showing both additive and dominant effects. There appeared to be no negative or 'protective' effect from the *DRB1\*0701* haplotype. *HLA-DPB1\*1301* was highly significantly associated with ATA when all ethnic groups were combined (p\<0.0001, OR = 9.96) (supplementary table 7). Using logistic regression, there was no evidence of gene--gene interaction between *DPB1\*1301* and *DRB1\*1104* (p = 0.9863) or between *DPB1\*1301* and *DQB1\*0301* (p = 0.9999) in the ATA positive group or in the total SSc group.

ARA were found to be most strongly associated in white subjects with HLA-*DRB1\*0404* (OR = 5.13) and *DRB1\*11* alleles (OR = 1.55 for one copy, 6.78 for two copies), especially *DRB1\*1104* in additive and dominant models, respectively ([table 6](#T6){ref-type="table"}) (supplementary table 8). In addition, a positive recessive effect was seen from *DQB1\*03* alleles (OR = 2.38), especially *DQB1\*0301* (OR = 1.50 for one copy, 3.77 for two copies). In black patients, the strongest associations were with *DRB1\*08* alleles (OR = 3.92), primarily *DRB1\*0804* (OR = 2.98), along with *DQA1\*0501* (OR = 3.10 for one copy, 6.03 for two copies) in an additive model and *DQB1\*0301* (OR = 3.60) showing a dominant effect. Among Hispanic subjects, *DRB1\*11, DQA1\*0501* and the *DQB1 26* epitope showed possible weak positive correlations, but the strongest association was with *DQB1\*0301* (OR = 4.07).

Other autoantibodies and HLA {#s11}
----------------------------

The HLA-*DRB1\*1302*, *DQB1\*0604* haplotype was most strongly associated with AFA in white subjects (p=0.0003, OR=6.87), along with the *DQB1 26* epitope (p=0.0009, OR=1.60), while in black subjects *DRB1\*08* alleles (p=0.0003, OR=5.76), especially *DQB1\*0804* (p=0.002, OR=5.70), showed the strongest associations (supplementary tables 9 and 9a).

Anti-RNP, anti-Smith (Sm), anti-Ro/SSA and anti-La/SSB antibodies showed no significant HLA associations.

Discussion {#s12}
==========

new to this study was the finding that the African HLA-*DRB1\*0804* allele, along with *DQA1\*0501* and *DQB1\*0301*, showed the most significant associations in black subjects and recurred in those with diffuse disease, ATA, ARA and AFA.

Perhaps equally important was the susceptibility effect of other *DQB1* alleles (besides *\*0301* and *\*0501*) encoding polar amino acids at position 26 of the DQ β chain (*DQB1\*26 epi*). Previously, we reported this shared epitope in the antigen binding cleft to be most important in the ACA autoimmune response[@R25]; however, this current larger study suggests that it occurs in the majority of patients with SSc regardless of ethnicity or autoantibody.

A second unreported and potentially 'protective' haplotype in white subjects, HLA-*DRB1\*1501*, *DQA1\*0102*, *DQB1\*0602*, was significantly decreased in a recessive model in Caucasian subjects with SSc overall and in both limited and diffuse subgroups, as well as in those patients with ACA.

An HLA-*DPB1* allele, *DPB1\*1301* in a dominant model, showed the highest odds ratios in SSc (OR = 3.18) and in both the limited (OR = 4.20) and diffuse (OR = 4.38) forms in Caucasian subjects; however, these associations were completely explained by its strong correlation with ATA (OR = 14.02). Testing for LD of this *DPB1* allele with the *DRB1\*1104* and *DQB1\*0301* alleles showed that these were independently associated class II effects. Interestingly, the ATA response is strongly associated with pulmonary fibrosis in SSc and certain *HLA-DP* alleles have been clearly shown to promote susceptibility to occupationally acquired berylliosis, another fibrosing lung disease.[@R40]

Finally, ARA characteristically are markers of rapidly progressive skin thickening and renal crises and this study is the first to demonstrate that they occur in similar prevalences in each of these ethnic groups and are associated with certain class II MHC alleles.

In previous studies of HLA and ARA, there have been contradictory findings, perhaps because small samples have been studied.[@R28] [@R38] [@R39]
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